Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 28;10:1642. doi: 10.3389/fonc.2020.01642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Tian, Niu and Yao.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

A visual interaction map of the different targets of the different drugs. Preclinical data indicate that all eight targets shown in the figure play an important role in the progression of osteosarcoma. However, clinical trials in osteosarcoma have demonstrated the low efficacy of single-target therapy by inhibiting VEGFs (by bevacizumab), KIT and PDGFRs (by imatinib), and IGF-1R (by cixutumumab). The results of these clinical trials suggest that the inhibition of one type of targets in the treatment of osteosarcoma is not feasible. PFS, progression-free survival; TKI, tyrosine kinase inhibitor; PR, partial response; VEGFR, vascular endothelial growth factor receptor; KIT, stem cell factor receptor; RET, rearranged during transfection; FGFR1, fibroblast growth factor receptor; PDGFR, platelet-derived growth factor receptor; SD, stable disease.